Egetis Therapeutics AB (publ) (FRA:P0F)

Market Cap	194.68M +6.0%
Revenue (ttm)	5.01M -18.4%
Net Income	-30.15M
EPS	-0.08
Shares Out	n/a
PE Ratio	n/a
Forward PE	19.15
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	62
Open	0.4640
Previous Close	0.4500
Day's Range	0.4640 - 0.4640
52-Week Range	0.2495 - 0.5730
Beta	n/a
RSI	58.75
Earnings Date	Feb 26, 2026

About Egetis Therapeutics AB

Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company’s products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a debilitating rare disease with no available treatment. The company was ...

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 40
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: P0F

Financial Performance

In 2024, Egetis Therapeutics AB's revenue was 46.10 million, a decrease of -19.97% compared to the previous year's 57.60 million. Losses were -343.60 million, 5.11% more than in 2023.

Financial numbers in SEK